keyword
https://read.qxmd.com/read/38688309/failure-to-undergo-resection-following-neoadjuvant-therapy-for-resectable-pancreatic-cancer-a-secondary-analysis-of-swog-s1505
#21
JOURNAL ARTICLE
Jordan M Cloyd, Sarah Colby, Katherine A Guthrie, Andy M Lowy, E Gabrielle Chiorean, Phillip Philip, Davendra Sohal, Syed Ahmad
BACKGROUND: Neoadjuvant therapy (NT) is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), and yet reasons for not undergoing subsequent pancreatectomy are poorly understood. Given the importance of completing multimodality therapy, we investigated factors associated with failure to undergo surgical resection following NT for PDAC. METHODS: SWOG S1505 was a multicenter phase II randomized trial of preoperative mFOLFIRINOX or gemcitabine/nab-paclitaxel prior to planned pancreatectomy for patients with potentially resectable PDAC...
April 29, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38687687/the-efficacy-of-coaxial-percutaneous-iodine-125-seed-implantation-combined-with-arterial-infusion-chemotherapy-for-advanced-pancreatic-cancer-a%C3%A2-randomized-clinical-trial
#22
JOURNAL ARTICLE
HongXiang Yao, Ying ZhuGe, ShiXiang Jin, ShuiBing Chen, HengYiTing Zhang, Dong Zhang, ZhiGang Chen
BACKGROUND: This study aimed to evaluate the clinical efficacy of coaxial percutaneous Iodine-125 (125 I) seed implantation in combination with arterial infusion chemotherapy for the treatment of advanced pancreatic cancer (PC) through a randomized controlled trial. METHODS: A total of 101 patients with advanced PC were randomized into two groups: control group treated with systemic intravenous chemotherapy and experimental group that received 125 I seed implantation in combination with arterial infusion chemotherapy...
April 30, 2024: International Journal of Radiation Biology
https://read.qxmd.com/read/38686801/a-comparison-of-cardiovascular-disease-cancer-mortality-and-graves-ophthalmopathy-following-treatment-for-hyperthyroidism-a-bayesian-network-meta-analysis
#23
COMPARATIVE STUDY
Xiaodong Liu, Carlos K H Wong, Tingting Wu, Wendy W L Chan, Yu Cho Woo, Cindy L K Lam, Brian H H Lang
OBJECTIVES: This network meta-analysis aimed to evaluate the association of anti-thyroid drugs (ATD), radioactive iodine (RAI), and thyroidectomy with subsequent outcomes in patients with newly-diagnosed hyperthyroidism. METHODS: The Ovid Medline, Ovid Embase, and Cochrane Library databases were searched for observational studies and randomized controlled trials. Included studies were published on or before 1st May 2022 involving at least two of the treatments among ATD, RAI, and thyroidectomy for hyperthyroidism...
February 2024: World Journal of Surgery
https://read.qxmd.com/read/38686358/the-role-of-direct-oral-anticoagulants-in-the-treatment-of-cancer-associated-venous-thromboembolism-review-by-middle-east-and-north-african-experts
#24
REVIEW
Shouki Bazarbashi, Heba Mohamed El Zawahry, Tarek Owaidah, Mohammad A AlBader, Ashraf Warsi, Mahmoud Marashi, Emad Dawoud, Hassan Jaafar, Sherif M Sholkamy, Fady Haddad, Alexander T Cohen
Venous thromboembolism is a leading cause of morbidity and mortality in patients with active cancer who require anticoagulation treatment. Choice of anticoagulant is based on careful balancing of the risks and benefits of available classes of treatment: vitamin K antagonists, low-molecular-weight heparin (LMWH), and direct oral anticoagulants (DOACs). Results from randomized controlled trials have shown the consistent efficacy of DOACs versus LMWH in the treatment of cancer-associated venous thromboembolism (VTE)...
2024: Journal of Blood Medicine
https://read.qxmd.com/read/38686198/short-and-long-term-outcomes-after-surgical-treatment-of-5918-patients-with-splenic-flexure-colon-cancer-by-extended-right-colectomy-segmental-colectomy-and-left-colectomy-a-systematic-review-and-meta-analysis
#25
Yu Cao, Mingze He, Kuo Chen, Zheng Liu, Denis I Khlusov, Tatyana V Khorobrykh, Xinren Cao, Polina D Panova, Sergey K Efetov, Airazat M Kazaryan
BACKGROUND: Colorectal cancer is among the most common cancers in the world, and splenic flexure colon cancer accounts for about 2-5% of them. There is still no consensus on the surgical treatment of splenic flexure colon cancer (SFCC), and the extent of surgical resection and lymph node dissection for SFCC is still controversial. AIM: To compare the postoperative and long-term oncologic outcomes of extended right colectomy (ERC), segmental colectomy (SC) and left colectomy (LC) for SFCC...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38686197/evaluating-first-line-therapeutic-strategies-for-metastatic-castration-resistant-prostate-cancer-a-comprehensive-network-meta-analysis-and-systematic-review
#26
Duojie Zhang, Haimin Weng, Zhangji Zhu, Weilun Gong, Yinfeng Ma
OBJECTIVE: This study aimed to evaluate the relative efficacy and safety of first-line treatment options for metastatic castration-resistant prostate cancer (mCRPC). METHODS: We systematically searched electronic databases, including PubMed and Web of Science, for studies published from their inception to April 3rd, 2023. Inclusion criteria were: 1) Completed Phase III or IV randomized controlled trials (RCTs) registered on ClinicalTrials.gov; 2) Patients with a confirmed diagnosis of mCRPC who had not previously received chemotherapy or novel endocrine therapies...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38684948/progression-free-survival-as-a-surrogate-endpoint-for-overall-survival-in-patients-with-relapsed-or-refractory-multiple-myeloma
#27
JOURNAL ARTICLE
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar
OBJECTIVES: The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multiple myeloma (RRMM) based on published randomized controlled trials (RCTs). METHODS: Two bibliographic databases (PubMed and Embase, 1970-2017) were systematically searched for RCTs in RRMM that reported OS and PFS, followed by an updated search of studies published between 2010 and 2022 in 3 databases (Embase, MEDLINE, and EBM Reviews, 2010-2022)...
April 29, 2024: BMC Cancer
https://read.qxmd.com/read/38684918/two-year-long-term-follow-up-of-treatment-with-the-optilume-bph-catheter-system-in-a-randomized-controlled-trial-for-benign-prostatic-hyperplasia-the-pinnacle-study
#28
JOURNAL ARTICLE
Steven A Kaplan, Jared L Moss, Sheldon J Freedman
BACKGROUND: Patient outcomes were assessed 2 years after treatment with the Optilume BPH Catheter System, a minimally invasive surgical therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). METHODS: One-hundred forty-eight adult males with symptomatic BPH were enrolled and randomized in a 2:1 fashion to Optilume BPH or Sham (100 Optilume BPH; 48 Sham). Long-term measures include International Prostate Symptom Score (IPSS), peak urinary flow rate (Qmax), Post-Void Residual Urine (PVR), quality of life measures and sexual function...
April 29, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38684254/financial-incentive-interventions-for-smoking-cessation-among-chinese-smokers-study-protocol-for-a-cluster-randomised-controlled-trial
#29
JOURNAL ARTICLE
Xiaochen Yang, Omar Galárraga, Wangnan Cao, Haoxiang Lin, Fei Cao, Chun Chang
INTRODUCTION: There is an urgent issue to relieve the burdens caused by tobacco use through feasible and effective smoking cessation interventions, particularly in a middle-income country with less accessible smoking cessation services and high demand for quitting smoking. Financial incentives have shown effective in changing health behaviours, thus needing to test its portability to a wider implementation and effectiveness of increasing smoking cessation rates. METHODS AND ANALYSIS: This is a three-arm cluster randomised controlled trial...
April 29, 2024: BMJ Open
https://read.qxmd.com/read/38683829/the-relative-risk-of-immune-checkpoint-inhibitor-pneumonitis-in-advanced-non-small-cell-lung-cancer-meta-analyses-of-controlled-clinical-trials
#30
JOURNAL ARTICLE
Ying Kong, Liang Hong, Xiao-Cheng Xu, Yun-Feng Chen, Jia Xu
OBJECTIVE: Immune checkpoint inhibitor pneumonitis (CIP) is a prevalent form of immunotherapy-induced pulmonary toxicity, ranking among the leading causes of mortality associated with immune checkpoint inhibitors (ICIs). Despite its significance, the risk stratification of CIP in advanced non-small cell lung cancer (NSCLC) remains uncertain. In this study, we conducted a comprehensive analysis, comparing various factors such as histological types, treatment regimens, PD-L1 expression levels, and EGFR/ALK negativity in advanced NSCLC...
2024: PloS One
https://read.qxmd.com/read/38683596/aspirin-vs-placebo-as-adjuvant-therapy-for-breast-cancer-the-alliance-a011502-randomized-trial
#31
JOURNAL ARTICLE
Wendy Y Chen, Karla V Ballman, Ann H Partridge, Olwen M Hahn, Frederick M Briccetti, William J Irvin, Banu Symington, Kala Visvanathan, Paula R Pohlmann, Thomas H Openshaw, Anna Weiss, Eric P Winer, Lisa A Carey, Michelle D Holmes
IMPORTANCE: Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to prevent breast cancer recurrence are lacking. OBJECTIVE: To determine whether aspirin decreases the risk of invasive cancer events among survivors of breast cancer. DESIGN, SETTING, AND PARTICIPANTS: A011502, a phase 3, randomized, placebo-controlled, double-blind trial conducted in the United States and Canada with 3020 participants who had high-risk nonmetastatic breast cancer, enrolled participants from 534 sites from January 6, 2017, through December 4, 2020, with follow-up to March 4, 2023...
April 29, 2024: JAMA
https://read.qxmd.com/read/38681121/topic-highlight-on-texture-and-color-enhancement-imaging-in-gastrointestinal-diseases
#32
EDITORIAL
Osamu Toyoshima, Toshihiro Nishizawa, Keisuke Hata
Olympus Corporation developed texture and color enhancement imaging (TXI) as a novel image-enhancing endoscopic technique. This topic highlights a series of hot-topic articles that investigated the efficacy of TXI for gastrointestinal disease identification in the clinical setting. A randomized controlled trial demonstrated improvements in the colorectal adenoma detection rate (ADR) and the mean number of adenomas per procedure (MAP) of TXI compared with those of white-light imaging (WLI) observation (58.7% vs 42...
April 14, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38680517/guideline-for-the-management-of-clostridioides-difficile-infection-in-pediatric-patients-with-cancer-and-hematopoietic-cell-transplantation-recipients-2024-update
#33
REVIEW
Priya Patel, Paula D Robinson, Brian T Fisher, Robert Phillips, Jessica E Morgan, Thomas Lehrnbecher, Susan Kuczynski, Christa Koenig, Gabrielle M Haeusler, Adam Esbenshade, Caitlin Elgarten, Nathan Duong, Caroline Diorio, Elio Castagnola, Melissa P Beauchemin, Roland A Ammann, L Lee Dupuis, Lillian Sung
Our objective was to update a clinical practice guideline for the prevention and treatment of Clostridioides difficile infection (CDI) in pediatric patients with cancer and hematopoietic cell transplantation recipients. We reconvened an international multi-disciplinary panel. A systematic review of randomized controlled trials (RCTs) for the prevention or treatment of CDI in any population was updated and identified 31 new RCTs. Strong recommendations were made to use either oral metronidazole or oral vancomycin for non-severe CDI treatment, and to use either oral vancomycin or oral fidaxomicin for severe CDI...
June 2024: EClinicalMedicine
https://read.qxmd.com/read/38680290/treatment-with-nanosomal-paclitaxel-lipid-suspension-versus-conventional-paclitaxel-in-metastatic-breast-cancer-patients-a-multicenter-randomized-comparative-phase-ii-iii-clinical-study
#34
JOURNAL ARTICLE
Chiradoni Thungappa Satheesh, Rakesh Taran, Jitendra Kumar Singh, Shanti Prakash Shrivastav, Nikunj K Vithalani, Kalyan Kusum Mukherjee, Rajnish Vasant Nagarkar, Tanveer Maksud, Ajay Omprakash Mehta, Krishnan Srinivasan, Mummaneni Vikranth, Satish Ramkrishna Sonawane, Ateeq Ahmad, Saifuddin Sheikh, Shoukath M Ali, Ronak Patel, Mahesh Paithankar, Lav Patel, Anil Rajani, Deepak Bunger, Alok Chaturvedi, Imran Ahmad
BACKGROUND: A novel nanosomal paclitaxel lipid suspension (NPLS), free from Cremophor EL (CrEL) and ethanol, was developed to address the solvent-related toxicities associated with conventional paclitaxel formulation. OBJECTIVE: To evaluate the efficacy and safety of NPLS versus CrEL-based paclitaxel (conventional paclitaxel) in patients with metastatic breast cancer (MBC). DESIGN: A prospective, open-label, randomized, multiple-dose, parallel, phase II/III study...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38680089/benefits-and-risks-of-clofarabine-in-adult-acute-lymphoblastic-leukemia-investigated-in-depth-by-multi-state-modeling
#35
RANDOMIZED CONTROLLED TRIAL
Sjoerd J F Hermans, Yvette van Norden, Jurjen Versluis, Anita W Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J Biemond, Arjan A van de Loosdrecht, Lotte E van der Wagen, Mar Bellido, Michel van Gelder, Walter J F M van der Velden, Dominik Selleslag, Daniëlle van Lammeren-Venema, Vincent H J van der Velden, Liesbeth C de Wreede, Douwe Postmus, Francesco Pignatti, Jan J Cornelissen
BACKGROUND: We recently reported results of the prospective, open-label HOVON-100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first-line treatment with or without clofarabine (CLO). No improvement of event-free survival (EFS) was observed, while a higher proportion of patients receiving CLO obtained minimal residual disease (MRD) negativity. AIM: In order to investigate the effects of CLO in more depth, two multi-state models were developed to identify why CLO did not show a long-term survival benefit despite more MRD-negativity...
May 2024: Cancer Medicine
https://read.qxmd.com/read/38679994/a-comparative-study-of-clinical-outcomes-in-locally-advanced-cervical-cancer-external-beam-radiotherapy-ebrt-and-sequential-high-dose-rate-intracavitary-brachytherapy-hdricbt-with-or-without-concurrent-cisplatin-on-the-day-of-icbt-insertion-a-tertiary-care
#36
RANDOMIZED CONTROLLED TRIAL
Shamila Alim, Shahid Ali Siddiqui, Mohd Akram, Seema Hakim, Mohd Asif Khan
OBJECTIVE: The current study aimed to delve into the comparative clinical outcomes between external beam radiation therapy (EBRT) and sequential High Dose Rate Intracavitary Brachytherapy (HDRICBT) with or without concurrent cisplatin administration on the day of intracavitary brachytherapy (ICBT) insertion in women with locally advanced cervical cancer. METHODS: In this study, conducted between January 2017 and July 2018 at a leading institute in India, diagnosed and untreated patients of locally advanced carcinoma cervix were randomized into two groups...
April 1, 2024: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/38679992/the-impact-of-tumor-hypoxia-modulation-on-sil-2r-levels-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl-patients-undergoing-chemotherapy-a-randomized-clinical-trial
#37
RANDOMIZED CONTROLLED TRIAL
Daniel Rizky, Kevin Tandarto, Eko Adhi Pangarsa, Ridho M Naibaho, Sigit P Kurniawan, Damai Santosa, Budi Setiawan, Catharina Suharti
OBJECTIVE: Tumor hypoxia induces the production of Hypoxia-Inducible Factor (HIF)-1 alpha, which interacts with NF-kB, leading to cancer proliferation and metastasis. This study investigated the effect of tumor hypoxia modulation using carbogen (95% O2 and 5% CO2) and nicotinamide on reducing soluble interleukin-2 receptor (sIL-2R) levels in newly diagnosed DLBCL patients with tissue overexpression of HIF-1α ≥10%. MATERIAL AND METHODS: A prospective randomized controlled clinical trial was conducted at Dr...
April 1, 2024: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/38679627/the-real-world-data-of-immune-checkpoint-inhibitor-combination-therapy-for-unresectable-or-metastatic-esophageal-cancer-a-multi-institutional-cohort-study
#38
JOURNAL ARTICLE
Sho Sato, Takashi Ssuzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Chikara Kunisaki, Takashi Kosaka, Itaru Endo, Yasushi Ichikawa, Yutaka Miyawaki, Hiroshi Sato, Hideaki Shimada
BACKGROUND: The real-world efficacy, feasibility, and prognostic factors of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer are not fully established. METHODS: This multi-institutional retrospective cohort study evaluated 71 consecutive patients treated with immune-checkpoint inhibitor combination therapy for esophageal cancer between March 2021 and December 2022. We assessed tumor response, safety, and long-term survival...
April 28, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38679615/systematic-assessment-of-the-influence-of-quality-of-studies-on-mistletoe-in-cancer-care-on-the-results-of-a-meta-analysis-on-overall-survival
#39
JOURNAL ARTICLE
Jorina Hofinger, Lukas Kaesmann, Jens Buentzel, Martin Scharpenberg, Jutta Huebner
PURPOSE: Mistletoe treatment in cancer patients is controversial, and a Cochrane review concluded that due to heterogeneity, performing a meta-analysis was not suitable. However, several systematic reviews included meta-analyses in favor of mistletoe. The aim of this work was to assess the influence of the methodological quality of controlled studies on the results of a meta-analysis regarding overall survival. METHODS: Between April and August 2022, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and Web of Science were systematically searched...
April 29, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38678796/meta-analysis-of-the-efficacy-of-neoadjuvant-chemotherapy-for-locally-advanced-cervical-cancer
#40
REVIEW
Daying Wang, Xiuli Fang
BACKGROUND: Neither improvements in surgical techniques and methods nor advances in radiotherapy equipment and techniques have significantly improved cervical cancer survival rates for quite some time. AIM: By comparing the effectiveness of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer, this study aimed to explore effective treatment methods for locally advanced cervical cancer, and provide a theoretical basis to guide clinical practice...
April 18, 2024: European Journal of Obstetrics, Gynecology, and Reproductive Biology
keyword
keyword
17438
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.